OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HOEC.PSX56

Hoechst Pakistan Ltd

PharmaceuticalsVerified

Hoechst Pakistan Ltd maintains a strong liquidity position with a current ratio of 1.65, indicating the company can cover its short-term obligations with its current assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. The operating cash flow of PKR 474.13 million and free cash flow of PKR 171.19 million further support its liquidity position. The company's profitability is reflected in its return on equity (ROE) of 8.16% and return on assets (ROA) of 4.08%. These metrics are in line with the industry's preferred metrics of ROE and ROA, which are used to assess the efficiency of capital deployment and asset utilization in the pharmaceutical sector. The net income of PKR 490.19 million and operating income of PKR 987.14 million indicate a healthy margin profile. Hoechst Pakistan Ltd operates as a single business segment, with all revenue generated domestically in Pakistan. The company does not disclose any geographic diversification, and its revenue is entirely concentrated within the local market. This concentration may expose the company to regional economic and regulatory risks. The company's growth trajectory is supported by its operating cash flow and free cash flow, which provide flexibility for reinvestment or shareholder returns. While no specific revenue growth targets are disclosed, the company's financial performance suggests a stable and profitable business model. The capital expenditure of PKR -242.21 million indicates a reduction in investment in physical assets, which may reflect a focus on optimizing existing operations. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure is free of long-term debt, and there are no signs of dilution pressure from recent equity issuances or shelf registration. The absence of dilution risk supports the company's financial stability and shareholder value preservation. No recent filings or transcripts were identified in the available source documents to provide additional insight into the company's operations or strategic direction. The company's financial disclosures are consistent with its historical performance, and there are no material events reported that would significantly alter its business outlook.

30-day price · HOEC.PSX-187.00 (-4.5%)
Low$3813.10High$4400.00Close$3983.10As of12 May, 00:00 UTC
Profile
CompanyHoechst Pakistan Ltd
TickerHOEC.PSX
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Hoechst Pakistan Ltd is a pharmaceutical company that develops, manufactures, and distributes prescription drugs and over-the-counter medications in Pakistan.

Classification. Hoechst Pakistan Ltd is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Hoechst Pakistan Ltd maintains a strong liquidity position with a current ratio of 1.65, indicating the company can cover its short-term obligations with its current assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. The operating cash flow of PKR 474.13 million and free cash flow of PKR 171.19 million further support its liquidity position. The company's profitability is reflected in its return on equity (ROE) of 8.16% and return on assets (ROA) of 4.08%. These metrics are in line with the industry's preferred metrics of ROE and ROA, which are used to assess the efficiency of capital deployment and asset utilization in the pharmaceutical sector. The net income of PKR 490.19 million and operating income of PKR 987.14 million indicate a healthy margin profile. Hoechst Pakistan Ltd operates as a single business segment, with all revenue generated domestically in Pakistan. The company does not disclose any geographic diversification, and its revenue is entirely concentrated within the local market. This concentration may expose the company to regional economic and regulatory risks. The company's growth trajectory is supported by its operating cash flow and free cash flow, which provide flexibility for reinvestment or shareholder returns. While no specific revenue growth targets are disclosed, the company's financial performance suggests a stable and profitable business model. The capital expenditure of PKR -242.21 million indicates a reduction in investment in physical assets, which may reflect a focus on optimizing existing operations. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure is free of long-term debt, and there are no signs of dilution pressure from recent equity issuances or shelf registration. The absence of dilution risk supports the company's financial stability and shareholder value preservation. No recent filings or transcripts were identified in the available source documents to provide additional insight into the company's operations or strategic direction. The company's financial disclosures are consistent with its historical performance, and there are no material events reported that would significantly alter its business outlook.
Key takeaways
  • Hoechst Pakistan Ltd has a strong liquidity position with a current ratio of 1.65 and no long-term debt.
  • The company's ROE of 8.16% and ROA of 4.08% indicate efficient capital and asset utilization.
  • Revenue is entirely concentrated in Pakistan, exposing the company to regional economic and regulatory risks.
  • The company's capital expenditure is negative, suggesting a focus on optimizing existing operations rather than expansion.
  • There are no immediate liquidity or dilution risks, and the company's financial structure is stable.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyPKR
Revenue$7.04B
Gross profit$2.16B
Operating income$987.1M
Net income$490.2M
R&D
SG&A
D&A
SBC
Operating cash flow$474.1M
CapEx-$242.2M
Free cash flow$171.2M
Total assets$12.02B
Total liabilities$6.01B
Total equity$6.01B
Cash & equivalents
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$15.88B$1.46B$906.0M$742.8M
FY-3$18.56B$773.9M$166.8M-$408.9M
FY-2$21.37B$1.09B$360.8M$387.5M
FY-1$26.75B$3.62B$1.86B$1.13B
FY0$30.96B$5.05B$2.90B$111.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$9.27B$5.22B
FY-3$12.33B$5.03B
FY-2$9.87B$5.47B
FY-1$13.56B$6.81B
FY0$14.51B$8.19B
PeriodOCFCapExFCFSBC
FY-4$1.53B-$307.1M$742.8M
FY-3-$1.27B-$573.2M-$408.9M
FY-2$2.52B-$286.7M$387.5M
FY-1-$834.1M-$510.1M$1.13B
FY0$4.94B-$1.60B$111.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$7.04B$987.1M$490.2M$171.2M
FQ-6$7.19B$899.6M$378.9M-$22.60B
FQ-5$6.23B$1.05B$652.2M$23.28B
FQ-4$7.57B$1.11B$553.2M-$349.2M
FQ-3$8.72B$1.29B$789.8M-$384.9M
FQ-2$8.29B$1.55B$867.6M$283.7M
FQ-1$6.37B$1.10B$689.4M$563.1M
FQ0$7.70B$1.31B$710.9M$597.0M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$12.02B$6.01B
FQ-6$13.81B$6.15B
FQ-5$13.56B$6.81B
FQ-4$13.12B$7.37B
FQ-3$14.27B$7.10B
FQ-2$14.46B$7.48B
FQ-1$14.51B$8.19B
FQ0$15.19B$8.90B
PeriodOCFCapExFCFSBC
FQ-7$474.1M-$242.2M$171.2M
FQ-6-$1.45B-$23.06B-$22.60B
FQ-5-$834.1M-$510.1M$23.28B
FQ-4$3.35B-$983.2M-$349.2M
FQ-3$5.05B-$1.19B-$384.9M
FQ-2$5.06B-$1.37B$283.7M
FQ-1$4.94B-$1.60B$563.1M
FQ0$2.21B-$220.0M$597.0M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$6.01B
Net cash
Current ratio1.6
Debt/Equity0.0
ROA4.1%
ROE8.2%
Cash conversion97.0%
CapEx/Revenue-3.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricHOEC.PSXActivity
Op margin14.0%7.7% medp25 -2.4% · p75 15.5%above median
Net margin7.0%5.9% medp25 -3.8% · p75 12.8%above median
Gross margin30.6%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-3.4%-7.0% medp25 -14.9% · p75 -3.2%above median
Debt / equity0.0%25.0% medp25 3.8% · p75 63.3%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-11 00:35 UTC#f65fb51e
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 03:32 UTCJob: 2fff5b6f